Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials
2 recruiting trials for Homozygous Familial Hypercholesterolemia (HoFH). Eligibility criteria explained in plain English.
TrialFinderData lists 2 Homozygous Familial Hypercholesterolemia (HoFH) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) (1), University of Wisconsin, Madison (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Screening for FH (diagnostic_test, 1 trial).
Track Homozygous Familial Hypercholesterolemia (HoFH) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on...
This observational, multicenter, retrospective and prospective study aims to evaluate the impact of intensified lipid-lowering therapy including Evinacumab on coronary...
The ORIGIN-FH Study
The goal of this clinical trial is to identify different types of Familial Hypercholesterolemia (FH) in infants and newborns. Participants will: * undergo a cheek swab for...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Homozygous Familial Hypercholesterolemia (HoFH), with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Homozygous Familial Hypercholesterolemia (HoFH), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Homozygous Familial Hypercholesterolemia (HoFH), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.